NVAX
Novavax, Inc.NASDAQHealthcare$7.70-3.99%ClosedMarket Cap: $1.25B
As of 2026-04-06
Valuation
P/E (TTM)
2.85
PEG
0.01
P/B
-10.11
P/S
1.16
EV/EBITDA
2.65
DCF Value
$-72.94
FCF Yield
-19.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.3%
Operating Margin
41.3%
Net Margin
39.2%
ROE
-546.2%
ROA
37.4%
ROIC
64.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $147.1M | 82.9% | $21.0M | $17.5M | $0.11 | — |
| FY 2025 | $1.12B | 93.7% | $563.3M | $440.3M | $2.54 | — |
| Q3 2025 | $70.4M | 69.5% | $-178.0M | $-202.4M | $-1.25 | — |
| Q2 2025 | $239.2M | 94.1% | $105.7M | $106.5M | $0.60 | — |
| Q1 2025 | $666.7M | 97.9% | $515.5M | $518.6M | $2.93 | — |
| Q4 2024 | $88.3M | 58.5% | $-131.1M | $-81.0M | $-0.51 | — |
| FY 2024 | $682.2M | 70.3% | $-248.9M | $-187.5M | $-1.23 | — |
| Q3 2024 | $84.5M | 28.3% | $-134.0M | $-121.3M | $-0.76 | — |
| Q2 2024 | $415.5M | 88.9% | $161.0M | $162.4M | $0.99 | — |
| Q1 2024 | $93.9M | 48.0% | $-138.7M | $-147.6M | $-1.05 | — |
| Q4 2023 | $291.3M | 48.9% | $-183.6M | $-178.4M | $-1.44 | — |
| FY 2023 | $556.4M | 38.2% | $-566.5M | $-545.1M | $-5.41 | — |